Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry
- retrospective study
- propensity-matched
- risk-adjusted
+2 more
- propensity-matched
- risk-adjusted
Authors' conclusion
Among patients with diabetes who underwent PCI, preprocedural use of SGLT2i correlated with a lower risk of CA-AKI.
Study context
- Population
- Patients with diabetes undergoing percutaneous coronary intervention (PCI) enrolled in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium PCI registry, January 2022 to September 2023; patients on dialysis and those without post-PCI serum creatinine excludedpatients with diabetes who underwent PCI
- Participants
- 13,804 patients
- Exposure
- SGLT2i users were compared with nonusers with respect to contrast-associated acute kidney injury (CA-AKI) outcomes
- SGLT2i usersn = 2,186
- nonusersn = 11,618reference
Main finding
As reported in the abstract
CA-AKI (increase in serum creatinine of ≥0.5 mg/dL following PCI)
Observational data: associations, not effects.
Further findings
CA-AKI, propensity-matched, risk-adjusted analysis · propensity-matched, risk-adjusted
adjusted odds ratio 0.72 · P = 0.027
CA-AKI in higher-risk subgroups
- The protective effect of SGLT2i was preserved among higher-risk subgroups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry. Circ Cardiovasc Interv. Published 5 February 2026. doi:10.1161/circinterventions.125.015645
Summarised from the published abstract; every number is checked against it